Capecitabine Tablet, Film Coated
Product Images NDC 82249-210

Product Visual Gallery

This gallery contains 8 technical images submitted to the FDA as part of the official labeling for Capecitabine (NDC 82249-210). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Civicascript Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Capecitabine-150mg-60tab (Capecitabine 150mg 60tab)

Capecitabine 150 mg film-coated tablets label from CivicaScript LLC. The label shows the product name, strength, dosage form, quantity of 60 tablets, and storage instructions. It includes a barcode, QR code, and manufacturer information (Akem Laboratories Ltd., Mumbai, India).*

FDA Label Image

Capecitabine-500mg-120tab (Capecitabine 500mg 120tab)

Label for Capecitabine Tablets, USP 500 mg film-coated tablets in a package of 120 tablets. The label includes storage instructions, distributor CivicaScript LLC, and manufacturer Alkem Laboratories Ltd. It features a QR code, barcode, and dosage advisory text.*

FDA Label Image

Capecitabine-fig-1 (Capecitabine Fig 1)

A Kaplan-Meier survival curve comparing two treatment groups: Capecitabine (solid line) and 5-FU plus Leucovorin (dashed line). The y-axis represents survival probability, and the x-axis shows months since randomization up to 96 months. The number of patients at risk is listed below the graph at various time points for both groups.*

FDA Label Image

Capecitabine-fig-2 (Capecitabine Fig 2)

A survival plot comparing two treatment groups: 5-FU + Leucovorin (dashed line) and Capecitabine (solid line) over 96 months since randomization. The y-axis shows survival probability from 0.0 to 1.0, and the x-axis shows time in months. Risk table data is displayed below the graph for both groups at multiple time points.*

FDA Label Image

Capecitabine-fig-3 (Capecitabine Fig 3)

A Kaplan-Meier survival curve comparing estimated probability over time (days) between two groups: 5-FU plus Leucovorin (Mayo Regimen) and Capecitabine Tablets 1250 mg/m2 twice daily intermittent dosing. The x-axis represents time in days, and the y-axis shows the estimated probability, with the curves showing survival trends for the two treatments over time.*

FDA Label Image

Capecitabine-fig-4 (Capecitabine Fig 4)

A Kaplan-Meier survival curve comparing estimated probability over time (days) for two treatment groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine Tablets 1250 mg twice daily intermittently with Docetaxel 75 mg/sqm every 3 weeks (solid line). The graph shows survival probability declining over approximately 700 days with marked median survival points at about 128 and 186 days.*

FDA Label Image

Capecitabine-fig-5 (Capecitabine Fig 5)

A survival curve chart comparing estimated probability over time in days for two groups: Docetaxel 100 mg/sqm every 3 weeks (dashed line) and Capecitabine tablets 1250 mg/sqm twice daily intermittent with Docetaxel 75 mg/sqm every 3 weeks (solid line). The chart shows survival probabilities decreasing over approximately 800 days, with specific median survival times indicated by arrows at about 351.5 and 442 days.*

FDA Label Image

Capecitabine-str (Capecitabine Str)

Chemical structure of capecitabine showing its molecular components including fluorine and a carbamate side chain.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.